Support solutions for patients who are uninsured or lack coverage for EYLEA

EYLEA4U logo

Patient eligibility criteria

  • Uninsured or lacks coverage for EYLEA
  • Must be a resident of the United States or its territories or possessions
  • Must have a completed EYLEA4U® Enrollment Form with patient signature in Section 6.3
  • Demonstrates financial need
    • Annual household adjusted gross income (AGI) must satisfy 1 of the following:
      • AGI is $100,000 or less
      • AGI is $100,001–$150,000 AND patient's out-of-pocket drug costs for EYLEA account for ≥3% of patient's AGI
        • Documentation of patient's out-of-pocket drug costs for EYLEA is required and can include:
          • Practice receipt of patient payment for EYLEA, which must include the amount paid specifically for EYLEA; practice billing record; or statements showing the patient’s EYLEA drug expenses have been billed

Patients are eligible for assistance for up to 1 year and must reapply annually.

Your patient may qualify for the PAP. Call your Regional Business Manager or EYLEA4U at 1-855-EYLEA4U (1-855-395-3248), Option 4, or visit the EYLEA4U e-Portal to learn more.

EYLEA4U® will independently verify a patient's income with our income validation tool.*

  • *If the income validation tool is unable to return results, the patient will be required by EYLEA4U to provide proof of income. Proof of income may also be requested at any time for audit/verification.

Patient assistance coverage

If a patient is determined to lack coverage for EYLEA through a payer denial and the denial is unsuccessfully appealed, the provider may qualify for a replacement EYLEA vial free of charge.

EYLEA4U is with you every step of the PAP process

Once the Enrollment Form requesting the PAP is received, a Reimbursement Specialist will:

Verify the patient's eligibility criteria and physician's decision to treat

Uninsured or lacks coverage for EYLEA

Is a resident of the United States or its territories or possessions

Demonstrates financial need
• Supporting documentation required

Notify you of patient's eligibility and, if approved, will:

Coordinate shipment of EYLEA to your practice

Send you a confirmation letter regarding patient enrollment, along with a Product Request Form (PRF) for future PAP shipments.
• Proactively send the PRF a week before the next scheduled injection to coordinate shipment

For questions about applying for coverage, PAP eligibility criteria, or denied claims, call EYLEA4U at 1-855-EYLEA4U (1-855-395-3248), Option 4, Monday–Friday 9 AM–8 PM Eastern Time.

  • Because EYLEA is a physician-administered product with comprehensive insurance coverage, product may be administered to the patient prior to a determination of insurance coverage or eligibility for the PAP. If a patient is denied coverage, and if the denial is unsuccessfully appealed and the patient qualified for the PAP, EYLEA4U will provide the physician with a replacement vial free of charge. Subject to Regeneron policies.
Product Support

Find complete product support—guiding you through orders, returns, and more.

Learn how it works
Reimbursement Support

Get help navigating the reimbursement process. Find enrollment forms, sample appeal letters, and more.

See the details
News

Keep up to date on current EYLEA clinical information, events, and more.

Read the latest
Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information Important Prescribing Information

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.